SCHEMBL883331

SCHEMBL883331

C=C(O)[C@@H](Nc1cccc(C(F)(F)F)c1)C(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
MMP2 P08253 1/20 0.51
ALDH1A1 P00352 5/20 0.49
HTT P42858 3/20 0.49
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
RAB9A P51151 1/20 0.47
KDM4E B2RXH2 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
TP53 P04637 2/20 0.44
GAA P10253 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10273820 0.86 L3MBTL1 (0.50) CA12CA1MMP2ALDH1A1HTT
SCHEMBL1634810 0.85 SMN1; SMN2 (0.56) CA12CA1MMP2ALDH1A1HTT
SCHEMBL1634808 0.85 SMN1; SMN2 (0.56) CA12CA1MMP2ALDH1A1HTT
SCHEMBL3478958 0.80 MAPT (0.53) CA12CA1MMP2ALDH1A1HTT
SCHEMBL19708735 0.74 CA12 (0.55) CA12CA1MMP2ALDH1A1HTT
SCHEMBL8102985 0.74 CA12 (0.59) CA12CA1MMP2ALDH1A1HTT
SCHEMBL633235 0.74 CA12 (0.58) CA12CA1MMP2ALDH1A1HTT
SCHEMBL11206192 0.73 NPSR1 (0.60) CA12CA1MMP2ALDH1A1HTT
SCHEMBL11206190 0.73 NPSR1 (0.60) CA12CA1MMP2ALDH1A1HTT
SCHEMBL18838552 0.73 SMN1; SMN2 (0.70) CA12CA1MMP2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012040242-A1 SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2012-03-29 WO disclosed